
北美前列腺癌核医学市场预测至 2028 年 – COVID-19 影响和区域分析 – 按类型(PET 和 SPECT)、PET 产品(F-18、C-11 和 Ga68-PSMA)和结束用户(医院、诊所等)
No. of Pages: 114 | Report Code: BMIRE00025677 | Category: Life Sciences
No. of Pages: 114 | Report Code: BMIRE00025677 | Category: Life Sciences
PSA 水平的升高会增加患前列腺癌的风险。血液中的 PSA 水平以纳克每毫升 (ng/mL) 为单位。没有明确的分界点可以确定男性是否患有前列腺癌。在评估男性是否需要进一步检测时,许多医生选择 4 ng/mL 或更高的 PSA 临界值,而其他医生可能主张从较低水平开始,例如 2.5 或 3。因此,检测男性血液中的 PSA 水平可以检测出前列腺癌早期。此外,直肠指检 (DRE) 是另一种检测前列腺癌的方法。 检查期间,医生使用戴手套、润滑的手指来触摸前列腺。使用经过充分验证的生物标志物进行定期筛查可以更快地检测局部疾病。此外,区分低级别和高级别疾病对于避免不必要的活检、严重疾病的治疗不足和惰性疾病的过度治疗至关重要。
< /p>
借助新功能和技术,供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动北美前列腺癌核医学市场。 北美前列腺癌核医学市场预计在预测期内将以良好的复合年增长率增长。
北美前列腺癌核医学市场按类型、PET 产品、最终用户和国家/地区进行细分。根据类型,北美前列腺癌核医学市场分为PET和SPECT。 2022年,PET在北美前列腺癌核医学市场占据主导地位。根据PET产品,北美前列腺癌核医学市场分为F-18、C-11和Ga68-PSMA。 F-18细分市场在2022年主导北美前列腺癌核医学市场。根据最终用户,北美前列腺癌核医学市场分为医院、诊所和其他。 2022年,医院细分市场主导北美前列腺癌核医学市场。按国家划分,北美前列腺癌核医学市场分为美国、加拿大和墨西哥。 2022 年,美国市场主导北美前列腺癌核医学市场。
Blue Earth Diagnostics Limited;想象抗体;锔;欢欣鼓舞的放射制药公司; NCM-美国有限责任公司; ABX 高级生化化合物有限公司; Telix 制药有限公司;诺华公司;治疗诊断学; Altair 旗下的 Lantheus Medical Imaging, Inc. 和 Lantheus Medical Imaging, Inc. 是北美前列腺癌核医学市场的领先公司之一。
Strategic insights for North America Prostate Cancer Nuclear Medicine involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 258.86 Million |
Market Size by 2028 | US$ 474.22 Million |
Global CAGR (2022 - 2028) | 10.6% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 类型
|
Regions and Countries Covered | 北美
|
Market leaders and key company profiles |
The regional scope of North America Prostate Cancer Nuclear Medicine refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Prostate Cancer Nuclear Medicine Market is valued at US$ 258.86 Million in 2022, it is projected to reach US$ 474.22 Million by 2028.
As per our report North America Prostate Cancer Nuclear Medicine Market, the market size is valued at US$ 258.86 Million in 2022, projecting it to reach US$ 474.22 Million by 2028. This translates to a CAGR of approximately 10.6% during the forecast period.
The North America Prostate Cancer Nuclear Medicine Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Prostate Cancer Nuclear Medicine Market report:
The North America Prostate Cancer Nuclear Medicine Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Prostate Cancer Nuclear Medicine Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Prostate Cancer Nuclear Medicine Market value chain can benefit from the information contained in a comprehensive market report.